Drugs / ETX-19477
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1/2 | NCT06395519 | May 2024 → Dec 2026 expected | BRCA1-related cancer predisposition, BRCA2-related cancer predisposition, castration-resistant prostate carcinoma, colorectal cancer +4 | 858 Therapeutics, Inc. | Recruiting | No outcome recorded |
News releases announcing trial results or a regulatory action · 3
| Date | Issuer | Release |
|---|---|---|
| 2026-08-19 | 858 Therapeutics, Inc. | Regulatory 858 Therapeutics Announces FDA Fast Track Designation for PARG Inhibitor ETX-19477 for the Treatment of Patients with BRCA-Mutated, HR+/HER2- Unresectable or Metastatic Breast Cancer 8five8tx.com ↗ |
| 2026-05-21 | 858 Therapeutics, Inc. | Results 858 Therapeutics Announces Initial Data from First-in-Human Phase 1/2 Trial of PARG Inhibitor ETX-19477 to be Presented at 2026 ASCO Annual Meeting 8five8tx.com ↗
858 Therapeutics, a clinical-stage biotechnology company, today announced preliminary safety and efficacy data from its ongoing, first-in-human Phase 1/2 trial of PARG inhibitor ETX-19477. |
| 2026-01-08 | 858 Therapeutics, Inc. | Regulatory 858 Therapeutics Announces FDA Fast Track Designation for PARG Inhibitor ETX-19477 for the Treatment of Patients with BRCA-Mutated, Platinum-Resistant Ovarian Cancer Share 8five8tx.com ↗ |
All press releases naming this drug 4 releases
Evidence & citations 2 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | ETX-19477 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT06395519 ↗ |
| Modality | Small molecule | “ETX-19477, a novel reversible small molecule inhibitor of PARG” NCT06395519 ↗ |